血液凝固の写真・画像 : 報道写真・ニュース映像ならKYODO NEWS IMAGELINK(イメージリンク)

-

Boy with Haemophilia

Boy with Haemophilia, an inherited blood disorder in which the clotting factor is absent. The disorder is passed down by the mother who is not affected but whose male offspring have a fifty per cent chance of inheriting Haemophilia. From Jules Rengade、クレジット：Ｗｏｒｌｄ　Ｈｉｓｔｏｒｙ　Ａｒｃｈｉｖｅ／ニューズコム／共同通信イメージズ　※エディトリアル使用のみ。広告、プロモーション、商業目的での利用に関してはお問合せください。

商品コード: 2018110921773

-

Blood Transfusion: blood flowed from arm of donor

Blood Transfusion: blood flowed from arm of donor, left, into cup, and was then pumped from the bottom of cup and forced through canula into patient. Before use, apparatus immersed in tepid water to prevent coagulation. Engraving from technical dictionary c1880.、クレジット：Ｗｏｒｌｄ　Ｈｉｓｔｏｒｙ　Ａｒｃｈｉｖｅ／ニューズコム／共同通信イメージズ　※エディトリアル使用のみ。広告、プロモーション、商業目的での利用に関してはお問合せください。

商品コード: 2018110914983

1960年10月07日

Ruby Hirose, US biochemist and bacteriologist

Ruby Hirose (1904-1960), US biochemist and bacteriologist. Hirose carried out research into serums and antitoxins at the William S. Merrell laboratories in Ohio, USA. In 1940, she was among ten women recognized by the American Chemical Society for accomplishments in chemistry. She later made major contributions to the development of vaccines against infantile paralysis. Here, she is shown working on remedies for hay fever, using alum to increase its effectiveness.、クレジット：Ｓｃｉｅｎｃｅ　Ｐｈｏｔｏ　Ｌｉｂｒａｒｙ／共同通信イメージズ

商品コード: 2022082308106

1985年03月22日

エイズ患者第１号

１９８５年３月２２日、厚生省のエイズ調査検討委員会は、米国から一時帰国した独身男性（３６）を日本のエイズ患者第１号と認定した。日本では輸入した血液凝固因子製剤により、血友病患者が多く感染、新たな薬害問題となった＝１９８５（昭和６０）年３月２２日

商品コード: 2003073100014

2001年09月14日

都道府県の担当者会議危機管理の不十分さ露呈

）、科学４０１Ｓ、１７日付朝刊用、解禁厳守　　血液凝固第８因子製剤の供給不足に対処するため、厚生労働省で開かれた都道府県の担当者会議（９月３日）

商品コード: 2001091400128

2019年08月22日

Bayer expands production in Bitterfeld, Germany

22 August 2019, Saxony-Anhalt, Bitterfeld-Wolfen: Andrea Heym, Production Manager, inspects a new mixing plant for a drug to inhibit blood coagulation at the Bayer Bitterfeld GmbH site, which is due to start operation soon. The manufacturing plant and a new high-performance packaging plant will enable Bayer to expand its portfolio at the Bitterfeld site. In addition to the existing range of over-the-counter medicines, a prescription drug from Bitterfeld for the European market is now being added. Bayer Bitterfeld has been manufacturing drugs for more than 50 countries worldwide since 1995, including aspirin in all dosage forms. So far, 135 billion tablets have been produced at the site in Saxony-Anhalt. Photo: Hendrik Schmidt/dpa-Zentralbild/dpa、クレジット：ＤＰＡ／共同通信イメージズ

商品コード: 2019082604954

2019年08月22日

Bayer expands production in Bitterfeld, Germany

22 August 2019, Saxony-Anhalt, Bitterfeld-Wolfen: Frank Wilgmann (l), Managing Director of Bayer Bitterfeld GmbH, and Reiner Haseloff (CDU), Minister President of Saxony-Anhalt, are about to build a new mixing plant for a drug to inhibit blood coagulation at the site of Bayer Bitterfeld GmbH, which is due to start operation soon. The manufacturing plant and a new high-performance packaging plant will enable Bayer to expand its portfolio at the Bitterfeld site. In addition to the existing range of over-the-counter medicines, a prescription drug from Bitterfeld for the European market is now being added. Bayer Bitterfeld has been manufacturing drugs for more than 50 countries worldwide since 1995, including aspirin in all dosage forms. So far, 135 billion tablets have been produced at the site in Saxony-Anhalt. Photo: Hendrik Schmidt/dpa-Zentralbild/dpa、クレジット：ＤＰＡ／共同通信イメージズ

商品コード: 2019082604875

2019年08月22日

Bayer expands production in Bitterfeld, Germany

22 August 2019, Saxony-Anhalt, Bitterfeld-Wolfen: Andrea Heym, Production Manager, inspects a new mixing plant for a drug to inhibit blood coagulation at the Bayer Bitterfeld GmbH site, which is due to start operation soon. The manufacturing plant and a new high-performance packaging plant will enable Bayer to expand its portfolio at the Bitterfeld site. In addition to the existing range of over-the-counter medicines, a prescription drug from Bitterfeld for the European market is now being added. Bayer Bitterfeld has been manufacturing drugs for more than 50 countries worldwide since 1995, including aspirin in all dosage forms. So far, 135 billion tablets have been produced at the site in Saxony-Anhalt. Photo: Hendrik Schmidt/dpa-Zentralbild/ZB、クレジット：ＤＰＡ／共同通信イメージズ

商品コード: 2019082604773

2019年08月22日

Bayer expands production in Bitterfeld, Germany

22 August 2019, Saxony-Anhalt, Bitterfeld-Wolfen: Andrea Heym, Production Manager, inspects a new mixing plant for a drug to inhibit blood coagulation at the Bayer Bitterfeld GmbH site, which is due to start operation soon. The manufacturing plant and a new high-performance packaging plant will enable Bayer to expand its portfolio at the Bitterfeld site. In addition to the existing range of over-the-counter medicines, a prescription drug from Bitterfeld for the European market is now being added. Bayer Bitterfeld has been manufacturing drugs for more than 50 countries worldwide since 1995, including aspirin in all dosage forms. So far, 135 billion tablets have been produced at the site in Saxony-Anhalt. Photo: Hendrik Schmidt/dpa-Zentralbild/dpa、クレジット：ＤＰＡ／共同通信イメージズ

商品コード: 2019082605031

2021年05月23日

Covid-19 Vaccine in London, UK - 23 May 2021

May 23, 2021, London, United Kingdom: Information sheet on Covid-19 vaccination and blood clotting, which is handed to people after receiving their vaccine seen at a vaccination centre in London. (Credit Image: © Dinendra Haria/SOPA Images via ZUMA Wire)、クレジット：©Ｄｉｎｅｎｄｒａ　Ｈａｒｉａ／ＳＯＰＡ　Ｉｍａｇｅｓ　ｖｉａ　ＺＵＭＡ　Ｗｉｒｅ／共同通信イメージズ

商品コード: 2021052906633

2021年11月25日

出血傾向に心当たりは？

血液凝固異常症に気付くポイント

商品コード: 2021112507884

2021年11月25日

出血傾向に心当たりは？

血液凝固異常症に気付くポイント

商品コード: 2021112507885